Autres langues AnGes, Inc.

Actions

4563

JP3127700007

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 05/07/2024			Varia. 5j.	Varia. 1 janv.
45 ^JPY	+2,27 %		+2,27 %	-37,50 %

19/01	Eiger BioPharmaceuticals obtient l'autorisation de mise sur le marché pour le traitement d'une maladie génétique ultra rare	MT
18/01	Eiger BioPharmaceuticals, Inc. et son partenaire AnGes, Inc. reçoivent l'autorisation de commercialiser Zokinvy (Lonafarnib) pour le syndrome de la progéria de Hutchinson-Gilford et les laminopathies progéroïdes avec déficit de transformation au Japon	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AnGes : Strategic Change in Product Development -Collategene (HGF gene therapy product)	24/06
AnGes : Notice Concerning Supply Agreement for "Zokinvy"	06/06
AnGes : Tie2 receptor agonist (AV 001), co development product, received fast track designation from the U.S. FDA	29/05
AnGes : Notice of Launch Date for Zokinvy (Orphan Drug) for the Treatment of Progeria	23/05
AnGes : Consolidated Financial Report for the First Quarter 2024	10/05
AnGes : Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc.	08/05
AnGes : Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of Progeria	17/04
AnGes : Notice Regarding Eiger BioPharmaceuticals, Inc.	12/04
AnGes : Notice of Business Restructuring at Consolidated Subsidiary	15/03
AnGes : Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for FY2024	14/03
Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	19/01
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	19/01
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	18/01
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study	14/11
AnGes : Consolidated Financial Report for the Third Quater 2023	08/11
AnGes : Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan	18/10/23
AnGes : Consolidated Financial Report Q2 2023	09/08/23
AnGes : Consolidated Financial Report for the Second Quater 2023	09/08/23
Tupperware Brands Corporation : Plastic is fantastic	08/08/23
Tupperware Brands Corporation: le plastique, c'est fantastique	07/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues AnGes, Inc.

Actions

4563

JP3127700007

Autres langues

Filtres